UMVA has learned that UK researchers are racing against time to develop a new Ebola vaccine using the same viral vector platform that powered the Oxford/AstraZeneca COVID-19 jab.

UMVA has learned that UK researchers are racing against time to develop a new Ebola vaccine using the same viral vector platform that powered the Oxford/AstraZeneca COVID-19 jab.
